{
    "clinical_study": {
        "@rank": "156197", 
        "arm_group": {
            "arm_group_label": "Anthrax Vaccine Adsorbed", 
            "description": "Active duty women who received one or more doses of BioThrax while pregnant, with the onset of pregnancy defined as the first day of the last menstrual period, and all live born infants born to women who join the registry."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if inadvertent receipt of the BioThrax vaccine\n      during pregnancy is independently associated with adverse maternal, pregnancy, or infant\n      health outcomes."
        }, 
        "brief_title": "BioThrax\u00ae (Anthrax) Vaccine in Pregnancy Registry", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pregnancy Complications", 
            "Pregnancy Outcome", 
            "Congenital Abnormalities"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Anthrax", 
                "Pregnancy Complications"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will use a convenience sample and passive referral to enroll participants.\n\n      For the maternal outcome portion of the study, pregnant active duty women who consent to\n      join the registry are expected to complete several surveys over the course of their\n      pregnancy, including an initial enrollment survey, a follow-up survey at or after the 20th\n      week of pregnancy, and a post-delivery survey at two weeks after their delivery due date\n      (unless a pregnancy loss is reported in the 20 week survey).\n\n      Outcomes among infants born to women enrolled in the Registry whose pregnancies result in a\n      livebirth will be assessed with a survey during the post-delivery contact, again at 4 months\n      of age, with a final follow-up when the infant reaches one year of age."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female active duty service member\n\n          -  Received one or more dose of BioThrax while pregnant, with the onset of pregnancy\n             defined as the first day of the last menstrual period.\n\n        Exclusion Criteria:\n\n          -  Non-service member, non-active duty pregnant female."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Active duty female service members who received one or more doses of BioThrax\u00ae while\n        pregnant, with the onset of pregnancy defined as the first day of the last menstrual\n        period (LMP) All live born infants born to women who join the registry."
            }
        }, 
        "enrollment": {
            "#text": "580", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653392", 
            "org_study_id": "EBS.AVA.010 / NHRC.2012.0003"
        }, 
        "intervention": {
            "arm_group_label": "Anthrax Vaccine Adsorbed", 
            "description": "This is an observational study, therefore no interventions are specified.", 
            "intervention_name": "Observational Intervention", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Maternal Mortality", 
            "Obstetric Labor, Premature", 
            "Eclampsia", 
            "Pre-Eclampsia", 
            "Abortion, Spontaneous", 
            "Diabetes, Gestational", 
            "Pregnancy, Ectopic", 
            "Hydatidiform Mole", 
            "Fetal death", 
            "Live birth", 
            "Still birth", 
            "Premature Birth", 
            "Sex ratio", 
            "Birth weight"
        ], 
        "lastchanged_date": "January 17, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92106"
                }, 
                "name": "Naval Health Research Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "BioThrax\u00ae (Anthrax) Vaccine in Pregnancy Registry", 
        "overall_contact": {
            "email": "NHRC-VaccineRegistry@med.navy.mil", 
            "last_name": "Ava Marie S Conlin, DO, MPH", 
            "phone": "619-553-9255"
        }, 
        "overall_official": {
            "affiliation": "Naval Health Research Center", 
            "last_name": "Ava Marie S Conlin, DO, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Pregnancy outcomes measured include live birth, still birth, spontaneous abortion, elective termination, ectopic pregnancy, or molar pregnancy Note: Twin or higher order multiple pregnancies may have more than one outcome.", 
                "measure": "Pregnancy Outcomes", 
                "safety_issue": "No", 
                "time_frame": "Up to 44 weeks"
            }, 
            {
                "description": "Maternal outcomes measured include maternal death, pre-eclampsia/eclampsia, preterm labor, and gestational diabetes.", 
                "measure": "Maternal Outcomes", 
                "safety_issue": "No", 
                "time_frame": "Up to 44 weeks"
            }, 
            {
                "description": "Infant outcomes measured include birth defects, infant sex ratios, preterm birth, and birth weight.", 
                "measure": "Infant Outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 year of age"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653392"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Emergent BioSolutions", 
        "sponsors": {
            "collaborator": {
                "agency": "Naval Health Research Center", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Emergent BioSolutions", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}